{"id":169824,"date":"2025-08-06T08:35:12","date_gmt":"2025-08-06T12:35:12","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169824"},"modified":"2025-08-06T14:59:15","modified_gmt":"2025-08-06T18:59:15","slug":"j-b-chemicals-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-up-9-net-profit-rises-14-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/j-b-chemicals-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-up-9-net-profit-rises-14-yoy\/","title":{"rendered":"J B Chemicals &#038; Pharmaceuticals Ltd Q1 FY26 Earnings Results \u2013 Revenue Up 9%, Net Profit Rises 14% YoY"},"content":{"rendered":"<p>J.B. Chemicals and Pharmaceuticals Limited (JBCPL), established in 1976, stands as one of India\u2019s prominent pharmaceutical firms with a strong integrated presence in both domestic and global markets. Renowned for its commitment to affordable, high-quality medicines, JBCPL continues to build trust among healthcare professionals and patients across geographies.<\/p>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/7563bee8-e089-47d0-bd87-0ad8ce728004.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26 Earnings Summary (Apr\u2013Jun 2025)<\/a><\/p>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b91,094 crore, up 8.96% year-on-year (YoY) from \u20b91,004 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b9837 crore, up 8.56% YoY from \u20b9771 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b9202 crore, up 14.12% from \u20b9177 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b912.97, up 13.87% from \u20b911.39 YoY.<\/li>\n<\/ul>\n<p><strong>Operational &amp; Strategic Update<\/strong><\/p>\n<ul>\n<li><strong>Robust Revenue Growth:<\/strong> The nearly 9% topline increase reflects strong sales momentum in core therapeutic areas, bolstered by steady demand in India and key international markets. Portfolio expansion and deepening of existing brands have contributed to overall growth.<\/li>\n<li><strong>Expense Management:<\/strong> Total expenses rose broadly in line with revenues, indicating effective cost management across manufacturing, R&amp;D, marketing, and distribution, which helped preserve operating margins.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/7563bee8-e089-47d0-bd87-0ad8ce728004.pdf\" target=\"_blank\" rel=\"noopener\">Profitability Expansion<\/a><strong>:<\/strong> Net profit and EPS grew at a faster pace than revenue, signifying improved margin performance and disciplined execution, supported by a favorable product mix and operational efficiencies.<\/li>\n<li><strong>Product Portfolio &amp; Market Focus:<\/strong> JBCPL continues to strengthen its market position in cardiovascular, gastrointestinal, and anti-infective therapies, with a growing presence in the US, Russia\/CIS, South Africa, and other regulated markets.<\/li>\n<li><strong>Innovation &amp; R&amp;D:<\/strong> Ongoing investment in research and launching differentiated formulations have enhanced the product pipeline, contributing to competitiveness in both acute and chronic therapeutic categories.<\/li>\n<li><strong>Global Reach:<\/strong> The company\u2019s international business remains a critical growth driver, benefiting from expanded regulatory approvals, quality certifications, and penetration across emerging and developed markets.<\/li>\n<\/ul>\n<p><strong>Corporate Developments<\/strong><\/p>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/7563bee8-e089-47d0-bd87-0ad8ce728004.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> marks another successful quarter for J B Chemicals &amp; Pharmaceuticals Ltd, combining healthy revenue gains with a strong uptick in profit\u2014evidence of resilient demand, robust cost controls, and effective strategic execution.<\/p>\n<p><strong>Looking Ahead<\/strong><\/p>\n<p>JBCPL is well-positioned to capitalize on emerging healthcare needs in India and abroad through portfolio expansion, continued investment in R&amp;D, and new market entries. The company\u2019s emphasis on quality, affordability, and sustainable growth should continue to deliver value for stakeholders through FY26 and beyond.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169825\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>J.B. Chemicals and Pharmaceuticals Limited (JBCPL), established in 1976, stands as one of India\u2019s prominent pharmaceutical firms with a strong integrated presence in both domestic and global markets. Renowned for its commitment to affordable, high-quality medicines, JBCPL continues to build trust among healthcare professionals and patients across geographies. Q1 FY26 Earnings Summary (Apr\u2013Jun 2025) Revenue: [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":169825,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-169824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169930,"url":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-q1-fy26-earnings-results-revenue-up-10-net-profit-rises-14-yoy\/","url_meta":{"origin":169824,"position":0},"title":"Alembic Pharmaceuticals Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 8, 2025","format":false,"excerpt":"Alembic Pharmaceuticals Limited is a leading player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates 3 R&D centers and 5 advanced manufacturing facilities, supporting global exports and a robust domestic presence. Presenting below are its Q1 FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"APLLTD Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":169824,"position":1},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172440,"url":"https:\/\/alphastreet.com\/india\/torrent-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":169824,"position":2},"title":"Torrent Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 17, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. \u00a0 Q2 FY26 Earnings Results: Revenue from Operations: \u20b93,302 crore, up 14% YoY from \u20b92,889 crore EBITDA: \u20b91,083 crore, up 15.3% YoY; EBITDA margin expanded to 32.8% (from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Torrent Pharmaceuticals Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171053,"url":"https:\/\/alphastreet.com\/india\/clean-science-q1-fy26-earnings-results\/","url_meta":{"origin":169824,"position":3},"title":"Clean Science Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 9, 2025","format":false,"excerpt":"Clean Science & Technology Ltd was incorporated in 2003 and is one of the leading global manufacturers of functionally critical specialty chemicals. Its portfolio includes performance chemicals such as MEHQ, BHA, and AP, pharmaceutical intermediates including Guaiacol and DCC, and FMCG chemicals like 4-MAP and Anisole. Q1 FY26 Earnings Results:\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"CLEAN Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169742,"url":"https:\/\/alphastreet.com\/india\/glaxosmithkline-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-down-1-net-profit-rises-13-yoy\/","url_meta":{"origin":169824,"position":4},"title":"GlaxoSmithKline Pharmaceuticals Ltd Q1 FY26 Earnings Results \u2013 Revenue Down 1%, Net Profit Rises 13% YoY","author":"Divyansh_Kasana","date":"August 4, 2025","format":false,"excerpt":"GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) is a leading pharmaceutical company focused on researching, manufacturing, and making available a broad range of medicines and vaccines that benefit people in India and globally. The company consistently delivers innovation and quality across its therapeutic portfolio. (Source: Company Website) Q1 FY26 Earnings Summary (Apr\u2013Jun\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169770,"url":"https:\/\/alphastreet.com\/india\/balaji-amines-ltd-q1-fy26-earnings-results-revenue-down-7-net-profit-falls-20-yoy\/","url_meta":{"origin":169824,"position":5},"title":"Balaji Amines Ltd Q1 FY26 Earnings Results \u2013 Revenue Down 7%, Net Profit Falls 20% YoY","author":"Divyansh_Kasana","date":"August 5, 2025","format":false,"excerpt":"Balaji Amines Limited is a leading manufacturer specializing in methylamines, ethylamines, derivatives of specialty chemicals, and pharma excipients. With a robust presence in the production of aliphatic amines, the company caters to diverse sectors including pharmaceuticals, agrochemicals, and user-specific specialty requirements. Balaji Amines is recognized as one of India\u2019s largest\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BALAMINES.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BALAMINES.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BALAMINES.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BALAMINES.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BALAMINES.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BALAMINES.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169824"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169824\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169825"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}